Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 10

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 10
---
375 which were registered upon the closing of the IPO in December 2024. In addition, each of the entities
agreed to and ultimately purchased 37,500 shares of the Company’s common stock at a purchase price of $1.33 per share prior to
the effective date of the IPO, resulting in aggregate proceeds of $150,000.

Pursuant
to the agreements, the counterparties are obligated to perform certain services, as defined, and the Company is recognizing the fair
value of the issued restricted shares as compensation expense over the 36-month term, the requisite service period. During the six months
ended June 30, 2025 the Company recorded compensation expense of $766,702 related to the agreement, which in general and administrative
expenses in the accompanying condensed consolidated statements of operations. There was no such expense recorded during the six months
ended June 30, 2024 due to the timing of the execution of the service agreements.

    16

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE
30, 2025

Note
6 – Stockholders’ Equity, continued

Stock
Options

The
Company grants stock under the provisions of its 2021 Equity Incentive Plan (“the
Plan”).

In
January 2024, the Company granted 180,000 stock options to a consultant with an exercise price of $1.33 per share and a grant date fair
value of $190,560, of which 50% vested immediately with the remaining 50% being vested over a 12 month period.

As
discussed in Note 3 – Related Party Transactions - Equity Instruments Exchanged for Accrued Compensation, during the six
months ended June 30, 2024, the Company issued additional options related to accrued compensation.

In
June 2025, the Company granted 250,000
stock options to a consultant with an exercise price of $0.97
per share and a grant date fair value of $191,168,
and a 10 year term. The 25% of the stock options vest immediately on the grant date, with the remaining 187,500 options vesting in equal
monthly installments ratably beginning in July 2025 through May 2027.

The
significant inputs utilized to determine the grant date fair value of stock options issued during the six month periods ended June
30